Letybo (Botulinum Toxin Type A)

Botulinum toxin type A cleaves the SNAP‑25 protein, which is essential for the fusion of synaptic vesicles with the nerve terminal membrane. This cleavage blocks the release of acetylcholine at the neuromuscular junction, preventing muscle contraction and resulting in a localized, reversible paralysis of the targeted muscle.

The appropriate dose of Letybo is determined by the prescribing clinician based on the specific indication, patient characteristics, and treatment goals. Dosing regimens vary widely across conditions and are individualized; therefore, no standard dose can be stated without a medical prescription.

Safety data for botulinum toxin type A during pregnancy or lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, visit the product page for Letybo on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and any necessary import documentation.

Letybo belongs to the same class of botulinum toxin type A products as other commercial brands such as Botox® and Dysport®. While the core mechanism is identical, differences may exist in formulation, unit potency, approved indications, and pricing. Clinicians choose a product based on clinical experience, regulatory approvals in their region, and specific patient needs.

Letybo must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Prior to use, the vial is typically allowed to reach room temperature and gently mixed if required by the manufacturer’s instructions.

Letybo is administered by a qualified healthcare professional via intramuscular injection. The injection sites are selected based on the targeted muscle group for the specific indication, and the dose is delivered using a sterile needle and syringe following aseptic technique.

Serious adverse events include the spread of toxin effect leading to generalized muscle weakness, dysphagia, respiratory compromise, and rare cases of anaphylaxis. Patients should be monitored closely after injection, especially for signs of systemic weakness or difficulty breathing, and seek immediate medical attention if such symptoms occur.

Letybo is contraindicated in individuals with known hypersensitivity to botulinum toxin type A preparations, as well as in patients with active infections at the proposed injection site. Caution is also advised for patients with neuromuscular disorders such as myasthenia gravis, Lambert‑Eaton syndrome, or those taking medications that potentiate neuromuscular blockade.